Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $37 million, a 24% increase compared to the prior year [10][17] - Software revenue was $24.7 million, consistent with expectations and similar to $24.3 million reported in Q3 2021 [17] - Drug discovery revenue was $12.3 million, up from $5.6 million in Q3 2021, driven by collaborations and milestone achievements [18] - Gross profit increased to $17.2 million, a 55% year-over-year increase [18] - Operating expenses rose to $63.4 million from $45.8 million in the same quarter last year [19] - Net loss for Q3 2022 was $39.9 million, compared to a net loss of $35 million in Q3 2021 [19] - Cash position at the end of Q3 was approximately $479 million, down from $513 million on June 30, 2022 [19] Business Line Data and Key Metrics Changes - The company has 18 proprietary drug discovery programs, with significant progress in both collaborative and proprietary projects [9][29] - Drug discovery revenue for the year is now expected to be between $45 million and $48 million, up from a previous expectation of $35 million to $45 million [23] Market Data and Key Metrics Changes - The company is experiencing strong growth in software licensing revenue, despite challenges in the macroeconomic environment [25] - The guidance for software revenue has been narrowed to a range of $122 million to $127 million for 2022, reflecting various market factors [21] Company Strategy and Development Direction - The company aims to accelerate growth in its software business and advance its drug discovery programs [5][11] - A partnership with Lilly was announced for the discovery of small molecule compounds, with potential milestone payments of up to $425 million [12][33] - The company is focused on maintaining a balanced business model that leverages its computational platform for drug discovery and materials design [9][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver continued growth despite a challenging economic environment [25][26] - The company is committed to advancing its proprietary programs and believes in the potential of its computational platform to create value [25][41] Other Important Information - The Phase 1 study of the MALT1 inhibitor, SGR-1505, is now open for patient enrollment [12][36] - The company plans to present new preclinical data for its CDC7 inhibitor, SGR-2921, at the ASH Annual Meeting [39] Q&A Session Summary Question: Impact of guidance components on software revenue - Management detailed the impact of foreign exchange, small biotech customers, and larger customers on software revenue guidance, indicating that all three factors contributed equally to the changes [44][47] Question: Details on MALT1 trial enrollment - Management confirmed that they are actively working on activating clinical sites in the U.S. and are considering global sites as well [48][51] Question: Increase in drug discovery guidance - The increase in drug discovery revenue guidance was attributed to successful advancements in collaborations and the recognition of previously deferred revenue [53][55] Question: BMS collaboration discontinuation - Management explained that BMS made a strategic decision to deprioritize a neuroscience program, but the company remains optimistic about the program's potential and will continue to invest internally [60][61] Question: Cash burn expectations - The company reported a cash burn of approximately $34 million for the quarter and expects cash burn to moderate as the software business grows [101][102]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 _____________________________________ ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2022 was $38.5 million, representing a 29% increase compared to Q2 2021 [9][17] - Software revenue was $30 million, a 25% growth year-over-year [8][17] - Drug discovery revenue was $8.5 million, up from $5.7 million in Q2 2021 [19] - Gross profit was $17.1 million, reflecting a 43% increase over the same quarter last year [19] - The company recorded a net loss of $47.7 million for Q2 2022, compared to a loss of $35 million in Q2 2021 [21] Business Line Data and Key Metrics Changes - Software revenue growth was driven by increased adoption from existing customers and new customer additions [18] - Drug discovery revenue included $5.4 million from collaboration with Bristol-Myers Squibb and preclinical milestones [19] Market Data and Key Metrics Changes - The company ended the quarter with approximately $513 million in cash, down from $529 million at the end of Q1 2022 [22] - The company expects software revenue for Q3 2022 to range from $23 million to $25 million, similar to Q3 2021 [24] Company Strategy and Development Direction - The company aims to accelerate growth in its software business and advance drug discovery programs [5] - The company is focused on maintaining a strong financial position to fund operations and advance clinical studies [10] - The company plans to continue investing in its platform and pipeline while pursuing profitability [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining full-year financial guidance despite anticipated fluctuations in software revenue [9][25] - The company expects total annual revenue to be between $161 million and $181 million, indicating 17% to 31% growth over 2021 [25] Other Important Information - The company submitted its first internal IND for the MALT1 inhibitor SGR-1505 and is preparing to initiate a Phase I trial [12][31] - The company has added four new early discovery programs in precision oncology and immunology [40] Q&A Session Summary Question: Clarification on Q3 software guidance and customer renewals - Management noted that Q3 is typically the lowest revenue quarter and there are fewer large customers up for renewal [49] Question: Customer spending patterns and ACV growth - Management indicated no signs of weakness in customer spending and maintained guidance for ACV growth in 2023 [51][52] Question: New business wins in life sciences and material sciences - Management highlighted that growth primarily comes from existing customers, with some new customer growth observed [58] Question: Internal capabilities for drug development - Management confirmed the addition of experts to the team to support upcoming clinical trials [60] Question: Visibility on new oncology and immunology programs - Management stated that new programs are being developed with a focus on differentiation and validation [64] Question: Details on the design of the SGR-1505 study - Management explained that the study aims to establish safety and tolerability, with pharmacokinetic and pharmacodynamic data being collected [68] Question: Impact of recent discontinuation of a Wee1 inhibitor on their program - Management expressed optimism about their Wee1 inhibitor program, emphasizing enhanced selectivity and drug-like properties [71]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4284541 (State or other jurisdiction of ...

Transforming Discovery of Therapeutics and Materials May 4, 2022 First Quarter 2022 Supplemental Slides Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding the potential advantages of our physics-b ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $48.7 million, a 51% increase compared to Q1 2021 [13] - Software revenue reached $33.1 million, representing a 26% growth year-over-year [13] - Drug discovery revenue was $15.6 million, up from $5.8 million in Q1 2021 [13] - Gross profit was $28 million, a 73% increase over the same period last year [14] - The company recorded a net loss of approximately $34.5 million for Q1 2022, compared to a loss of approximately $0.5 million in Q1 2021 [14][15] - Cash and cash equivalents at the end of the quarter were approximately $529 million, down from $579 million at the end of 2021 [15] Business Line Data and Key Metrics Changes - Software revenue growth was driven by increased adoption from existing customers and new customer additions [13] - Drug discovery revenue included $4 million from collaboration with Bristol-Myers Squibb and $9 million from preclinical milestones recognized earlier than expected [14] Market Data and Key Metrics Changes - The company expects total annual revenue to be in the range of $161 million to $181 million, reflecting 17% to 31% growth over 2021 [17] - Software revenue guidance for the year is projected between $126 million and $136 million, indicating 11% to 20% growth over 2021 [17] - Drug discovery revenue is expected to range from $35 million to $45 million, reflecting 42% to 82% growth over the previous year [18] Company Strategy and Development Direction - The company is focused on accelerating the growth of its software business and advancing drug discovery programs [5] - A new collaboration with Eonix aims to enhance the discovery and design of materials for lithium-ion batteries, marking the first equity-based collaboration in the materials science sector [10][11] - The company is committed to advancing its wholly-owned drug discovery programs, with several candidates expected to enter clinical trials [10][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum and ability to innovate while maintaining a solid revenue foundation [10] - The company is optimistic about the impact of its computational platform on drug discovery and materials science [9][10] - Management reaffirmed guidance for the full year, indicating confidence in achieving projected revenue despite potential fluctuations [16][17] Other Important Information - The company is continuing to invest in R&D and infrastructure to support growth [14] - The acquisition of XTAL is expected to enhance the company's capabilities in structural biology [15][49] Q&A Session Summary Question: Rationale for Eonix collaboration - Management highlighted the collaboration's goal of developing better batteries and the expected impact on advancing science and technology [30] Question: Drug discovery revenue cadence for 2022 - Management indicated that drug discovery revenue is not guided quarterly due to milestone timing variability, but the annual guidance remains [32][33] Question: Software revenue guidance and visibility - Management expressed confidence in the software revenue guidance, noting strong customer engagement and larger-than-expected renewals [40][61] Question: Retention rate and cash usage - Retention rate remains high, with management indicating continued investment in the platform and internal pipeline [77][78] Question: Update on sales team and large molecule traction - Management confirmed ongoing growth in the sales team and increasing traction with large molecule customers [83][86] Question: Growth prospects among existing customers - Management noted growth across both large and small customers, with significant potential remaining in large pharma accounts [90][94]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4284541 (State or other jurisdiction o ...

Transforming Discovery of Therapeutics and Materials February 24, 2022 Fourth Quarter and Full-Year 2021 Supplemental Slides Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding the potential advant ...

Financial Data and Key Metrics Changes - Total revenue for 2021 was $137.9 million, a 28% increase over the prior year, with Q4 software revenue reaching $38.6 million, a 55% increase compared to Q4 2020 [7][13] - Operating expenses for Q4 2021 were $48.9 million, up from $35.6 million in Q4 2020, reflecting increased investment in R&D [13] - The net loss for 2021 was $101.2 million compared to a loss of $26.6 million in 2020 [15] Business Line Data and Key Metrics Changes - Software revenue for the full year was $113.2 million, up 22% over 2020, driven by strong growth in both life sciences and material sciences [14] - Drug discovery revenue for 2021 was $24.7 million, compared to $15.6 million in 2020, primarily due to revenue recognized from collaboration with BMS [15] Market Data and Key Metrics Changes - Total software annual contract value (ACV) reached $112.1 million in 2021, a 22% increase year-over-year [16] - The number of customers with ACV over $1 million was 15, with total ACV in this category increasing to $40.2 million in 2021, up from $35.5 million in 2020 [16] Company Strategy and Development Direction - The company aims for ACV growth of over 20% in 2023 and expects drug discovery revenue of at least $100 million in 2023, excluding potential revenue from lead internal programs [20] - The acquisition of XTAL BioStructures is intended to enhance structural biology capabilities and support drug discovery efforts [8][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2022, expecting total annual revenue to be in the range of $161 million to $181 million, corresponding to 17% to 31% growth over 2021 [17] - The company anticipates continued strong growth in software revenue, with expectations for Q1 2022 software revenue to range from $28 million to $30 million [18] Other Important Information - The company established operations in Seoul, South Korea, and expanded operations in Hyderabad, India, to enhance competitive positioning [9] - Joel Lebowitz announced his retirement at the end of February 2022, with the company actively searching for his successor [11] Q&A Session Summary Question: What drove the strength in software revenue in Q4? - Management noted that the growth was driven by increased adoption of solutions by existing large customers and the addition of new customers [32] Question: How confident is the company in the drug discovery revenue guidance for 2023? - Management expressed confidence based on a broad portfolio of collaboration programs, with about 20 programs currently in the pipeline [34] Question: What is the status of the IND filing for the MALT1 program? - The company has completed GLP toxicology studies and is in the final planning phase for the IND submission, having interacted with the FDA [36] Question: What drives performance to either side of the software sales guidance for 2022? - Management indicated that performance is influenced by the commitment level of large customers to adopt solutions more extensively [40] Question: How does the company prioritize which programs to add to its pipeline? - The company focuses on targets with preclinical and human evidence, considering the clinical landscape and potential for compelling clinical data [46]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39206 Schrodinger, Inc. (Exact name of Registrant as specified in its Charter) Delaware 95-4284541 (State or other jurisdiction of in ...